Pacific Biosciences Of California (PACB) Profit After Tax (2010 - 2026)

Pacific Biosciences Of California's Profit After Tax history runs 17 years deep, the most recent figure standing at -$8.3 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 20082.93% year-over-year to -$8.3 million in Q1 2026; TTM through Mar 2026 was -$86.6 million, a 49.13% increase from a year earlier, with the FY2025 full-year figure at -$546.4 million, down 76.34% from the prior year.
• Profit After Tax grew to -$8.3 million in Q1 2026 per PACB's latest filing, from -$40.4 million in the prior quarter.
• Across five years, Profit After Tax topped out at $2.1 million in Q3 2024 and bottomed at -$173.3 million in Q2 2024.
• The 5-year median for Profit After Tax is -$69.8 million (2023), against an average of -$56.3 million.
• Across the five-year window, Profit After Tax surged 103.14% in 2024 and slumped 20082.93% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$84.4 million in 2022, then climbed by 5.24% to -$80.0 million in 2023, then soared by 101.3% to $1.0 million in 2024, then slumped by 3993.06% to -$40.4 million in 2025, then surged by 79.5% to -$8.3 million in 2026.
• Per Business Quant, the three latest PACB Profit After Tax figures stand at -$8.3 million (Q1 2026), -$40.4 million (Q4 2025), and -$37.9 million (Q3 2025).